These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 36142323)

  • 21. Amelioration of Murine Diabetic Nephropathy with a SGLT2 Inhibitor Is Associated with Suppressing Abnormal Expression of Hypoxia-Inducible Factors.
    Inada A; Inada O; Yasunami Y; Arakawa K; Nabeshima YI; Fukatsu A
    Am J Pathol; 2022 Jul; 192(7):1028-1052. PubMed ID: 35460614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia and the HIF system in kidney disease.
    Nangaku M; Eckardt KU
    J Mol Med (Berl); 2007 Dec; 85(12):1325-30. PubMed ID: 18026918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
    Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
    Tanaka T; Eckardt KU
    Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
    Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
    Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia signaling in renal pericytes-is it safe to activate?
    Herbek S; Edmonston DL; Souma T
    Kidney Int; 2021 Jun; 99(6):1267-1269. PubMed ID: 34023026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?
    Miyata T; Suzuki N; van Ypersele de Strihou C
    Kidney Int; 2013 Oct; 84(4):693-702. PubMed ID: 23486514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
    Sugahara M; Tanaka S; Tanaka T; Saito H; Ishimoto Y; Wakashima T; Ueda M; Fukui K; Shimizu A; Inagi R; Yamauchi T; Kadowaki T; Nangaku M
    J Am Soc Nephrol; 2020 Mar; 31(3):560-577. PubMed ID: 31996409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
    Yu X; Fang Y; Liu H; Zhu J; Zou J; Xu X; Jiang S; Ding X
    Nephrol Dial Transplant; 2012 Aug; 27(8):3110-9. PubMed ID: 22399494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
    Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
    Pan SY; Tsai PZ; Chou YH; Chang YT; Chang FC; Chiu YL; Chiang WC; Hsu T; Chen YM; Chu TS; Lin SL
    Kidney Int; 2021 Jun; 99(6):1354-1368. PubMed ID: 33812664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.
    Yu Y; Yang F; Yu Q; Liu S; Wu C; Su K; Yang L; Bao X; Li Z; Li X; Zhang X
    J Med Chem; 2021 Dec; 64(23):17384-17402. PubMed ID: 34709043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO.
    Singh AK
    Am J Nephrol; 2022; 53(5):361-365. PubMed ID: 35462362
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J; Xie QH; You L; Xu NX; Hao CM
    Pharmacol Res; 2021 Jan; 163():105256. PubMed ID: 33086081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence and expansion of hypoxia detected by pimonidazole adduct immunostaining during progression of diabetic nephropathy in diabetic mice.
    Inada A; Fukatsu A
    Am J Physiol Renal Physiol; 2023 Nov; 325(5):F527-F535. PubMed ID: 37615048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.
    Sugahara M; Tanaka T; Nangaku M
    Kidney360; 2020 Sep; 1(9):1021-1031. PubMed ID: 35369554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of extract of Pueraria tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats.
    Shukla R; Pandey N; Banerjee S; Tripathi YB
    Biomed Pharmacother; 2017 Sep; 93():276-285. PubMed ID: 28648975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic stabilization of hypoxia-inducible transcription factors protects developing mouse brain from hypoxia-induced apoptotic cell death.
    Trollmann R; Richter M; Jung S; Walkinshaw G; Brackmann F
    Neuroscience; 2014 Oct; 278():327-42. PubMed ID: 25162122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.